Osiris Therapeutics (Osiris Therapeutics) Change In Payables And Accrued Expense : $3.8 Mil (TTM As of Dec. 2018)

View and export this data going back to 2006. Start your Free Trial

What is Osiris Therapeutics Change In Payables And Accrued Expense?

Osiris Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2018 was $2.6 Mil. It means Osiris Therapeutics's Accounts Payable & Accrued Expense increased by $2.6 Mil from Sep. 2018 to Dec. 2018 .

Osiris Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2018 was $3.8 Mil. It means Osiris Therapeutics's Accounts Payable & Accrued Expense increased by $3.8 Mil from Dec. 2017 to Dec. 2018 .

Osiris Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Osiris Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Osiris Therapeutics Change In Payables And Accrued Expense Chart

Osiris Therapeutics Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

2.57

4.40

2.26

-1.09

3.85

Osiris Therapeutics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.70	2.92	-1.50	-0.21	2.64

Osiris Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.8 Mil.

Osiris Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Osiris Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Osiris Therapeutics (Osiris Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Osiris Therapeutics Inc (NAS:OSIR) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

7015 Albert Einstein Drive, Columbia, MD, USA, 21046-1707

Website

http://www.osiris.com

Osiris Therapeutics is a biotechnology company involved in researching, developing, and marketing cellular regenerative medicine products. The company's therapeutic areas focus on innovation in regenerative medicine, including bioengineering, stem cell research, and viable tissue-based products. Osiris has accomplished commercial success with products in orthopedics, sports medicine, and wound care, such as Cartiform, Ovation, and Grafix.

Executives

Reinhart Charles A. Iii	director	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Linda L Chang	officer: Chief Financial Officer	ONE PARK PLACE, STE 450, ANNAPOLIS MD 21401
Shauna L Vernal	officer: Chiel Legal Officer
Linda Palczuk	officer: President & CEO	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
David L White	director
Thomas J Knapp	director	4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
Jonathan Mark Hopper	officer: Chief Medical Officer	64 SIDNEY STREET, CAMBRIDGE MA 02139
Jacoby Philip R Jr	officer: Principal Accounting Officer
C Randal Mills	director, officer: President & CEO	18366 CALLE STELLINA, RANCHO SANTA FE CA 92091
Jay M Moyes	director
Stephen W Potter	officer: Senior Vice President	7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gregory Hurd Barnhill	director